Filing Details
- Accession Number:
- 0001735276-25-000032
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2025-03-05 16:21:52
- Reporting Period:
- 2025-03-03
- Filing Date:
- 2025-03-05
- Accepted Time:
- 2025-03-05 16:21:52
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1178670 | Alnylam Pharmaceuticals Inc. | ALNY | Pharmaceutical Preparations (2834) | 770602661 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1829252 | Pushkal Garg | 675 West Kendall Street Henri A. Termeer Square Cambridge MA 02142 | Cmo & Evp Dev & Med Affairs | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2025-03-03 | 14,137 | $0.00 | 27,099 | No | 4 | A | Direct | |
| Common Stock | Disposition | 2025-03-03 | 213 | $242.37 | 26,886 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2025-03-03 | 235 | $243.36 | 26,651 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2025-03-03 | 158 | $244.41 | 26,493 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2025-03-03 | 116 | $245.26 | 26,377 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2025-03-03 | 48 | $246.18 | 26,329 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2025-03-03 | 5 | $247.35 | 26,324 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2025-03-03 | 1 | $248.36 | 26,323 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2025-03-03 | 583 | $243.13 | 25,740 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2025-03-03 | 273 | $244.43 | 25,467 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2025-03-03 | 117 | $245.53 | 25,350 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2025-03-04 | 147 | $239.25 | 25,203 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2025-03-04 | 343 | $240.92 | 24,860 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2025-03-04 | 198 | $241.60 | 24,662 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2025-03-04 | 120 | $242.70 | 24,542 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | A | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Acquisiton | 2025-03-03 | 7,819 | $0.00 | 7,819 | $243.53 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 7,819 | 2035-03-03 | No | 4 | A | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 431 | Indirect | by Managed Account |
| Common Stock | 250 | Indirect | by Trust |
Footnotes
- These shares are represented by restricted stock units (RSUs) granted under the Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest over a three-year period, with one third vesting on each of the first, second and third anniversaries of the grant date, subject to the Reporting Persons continuous service with the Issuer as of each such vesting date.
- The Reporting Person has reported certain prior awards of RSUs in Table II of Form 4. The total reported in Column 5 includes the 14,137 newly awarded RSUs and 10,405 shares of common stock. The Reporting Person also holds 1,908 unvested RSUs that were previously reported in Table II.
- Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units.
- The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $241.87 to $242.86. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $242.89 to $243.88. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $243.90 to $244.90. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $244.91 to $245.88. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $246.00 to $246.71. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $247.04 to $247.52. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 11, 2024.
- The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $242.62 to $243.58. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $244.04 to $244.80. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $245.07 to $245.74. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $238.93 to $239.40. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $240.18 to $241.17. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $241.21 to $242.02. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $242.46 to $242.93. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- Reflects shares of ALNY common stock acquired by the Reporting Person under the issuer 401(k) plan as a result of the issuer 401(k) matching contribution program.
- Represents shares held in trust, of which the Reporting Persons spouse is co-trustee. The Reporting Person disclaims beneficial ownership of these shares, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
- The stock option vests as to 25% of the shares on the first anniversary of the grant date and the remaining shares vest in equal installments at the end of each successive three-month period thereafter until the fourth anniversary of the grant date, subject to the Reporting Persons continuous service with the Issuer as of each such vesting date.
Billionaire Hedge Funds
